Transforming growth factor beta-resistant natural killer cells
AssigneeResearch Institute At Nationwide Children's Hospital
InventorsDean Anthony LEE, Jennifer Ann FOLTZ-STRINGFELLOW, Jena EDWARDS-MOSEMAN
Life of this patent
Estimating the term…
Abstract
An NK cell with low SMAD3 expression and altered gene expression profile resulting in high cytokine expression and TGF-β superfamily resistance is described, refered to herein as TGF-β superfamily-imprinted Natural Killer Cells (TGFβi NK cells). A method of treating cancer or infection in a subject in need thereof is described. The method includes administering a therapeutically effective number of TGFβi NK cells to the subject. A method of producing TGFβi NK cells is described by in vitro activation of natural killer cells in the presence of a TGF-β superfamily cytokine.
Claims25
A method of treating cancer or an infectious disease in a subject in need thereof, comprising administering a therapeutically effective number of transforming growth factor-beta (TGF-β) Superfamily-Imprinted Natural Killer (TGFβi NK) cells to the subject.
(canceled)
(canceled)
(canceled)
A natural killer (NK) cell or NK cell line exhibiting increased resistance to a TGF-β superfamily cytokine.
(canceled)
(canceled)
A method of making a TGF-β-Superfamily Imprinted Natural Killer (TGFβi NK) cell line, comprising the in vitro activation of natural killer cells in the presence of a TGF-β-Superfamily cytokine.
Dependencies are inferred from the claim text.